Adults
Jump to topic
Behavioral Health Care - Adults | CMS Medicaid Adult Core Set - Standard Medicaid | Hospital Inpatient and Outpatient Care - Adults | Long Term Community Based Care - Adults | Pharmacy - AdultsBack to top
Behavioral Health Care - Adults
Back to top
CMS Medicaid Adult Core Set - Standard Medicaid
- Asthma in Younger Adults Admission Rate (PQI15)
- Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate (PQI05)
- Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate (PQI05): A. Age 40-64 Years
- Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate (PQI05): B. Age 65 and Older
- Concurrent Use of Opioids and Benzodiazepines (CUOB)
- Concurrent Use of Opioids and Benzodiazepines (CUOB): A. Age 18 to 64 Years
- Concurrent Use of Opioids and Benzodiazepines (CUOB): B. Age 65 and Older
- Contraceptive Care Postpartum Women (CCP): Long-Acting Reversible Method of Contraception – 3 days
- Contraceptive Care Postpartum Women (CCP): Long-Acting Reversible Method of Contraception – 3 days: A. Age 15–20
- Contraceptive Care Postpartum Women (CCP): Long-Acting Reversible Method of Contraception – 3 days: B. Age 21–44
- Contraceptive Care Postpartum Women (CCP): Long-Acting Reversible Method of Contraception – 90 days
- Contraceptive Care Postpartum Women (CCP): Long-Acting Reversible Method of Contraception – 90 days: A. Age 15–20
- Contraceptive Care Postpartum Women (CCP): Long-Acting Reversible Method of Contraception – 90 days: B. Age 21–44
- Contraceptive Care Postpartum Women (CCP): Most or Moderately Effective Contraception – 3 Days by Age Group
- Contraceptive Care Postpartum Women (CCP): Most or Moderately Effective Contraception – 3 Days by Age Group: A. Age 15–20
- Contraceptive Care Postpartum Women (CCP): Most or Moderately Effective Contraception – 3 Days by Age Group: B. Age 21–44
- Contraceptive Care Postpartum Women (CCP): Most or Moderately Effective Contraception – 90 days by Age Group
- Contraceptive Care Postpartum Women (CCP): Most or Moderately Effective Contraception – 90 days by Age Group: A. Age 15–20
- Contraceptive Care Postpartum Women (CCP): Most or Moderately Effective Contraception – 90 days by Age Group: B. Age 21–44
- Contraceptive Care – Women provided a long-acting reversible method of contraception (CCW)
- Contraceptive Care – Women provided a long-acting reversible method of contraception (CCW): A. Age 15 to 20 Years
- Contraceptive Care – Women provided a long-acting reversible method of contraception (CCW): B. Age 21 to 44 Years
- Contraceptive Care – Women provided a most effective or moderately effective method of contraception (CCW)
- Contraceptive Care – Women provided a most effective or moderately effective method of contraception (CCW): A. Age 15 to 20 Years
- Contraceptive Care – Women provided a most effective or moderately effective method of contraception (CCW): B. Age 21 to 44 Years
- Developmental Screening in the First Three Years of Life (DEV.02)
- Developmental Screening in the First Three Years of Life (DEV.02): A. Children Who Turned 1 year of Age During the Measurement Period
- Developmental Screening in the First Three Years of Life (DEV.02): B. Children Who Turned 2 Years of Age During the Measurement Period
- Developmental Screening in the First Three Years of Life (DEV.02): C. Children Who Turned 3 Years of Age During the Measurement Period
- Diabetes Care for People with Serious Mental Illness: Glycemic Status > 9.0% (HPCMI)
- Diabetes Care for People with Serious Mental Illness - HA1c Testing Poor Control (>9%) (HPCMI): A. Age 18-64 Years
- Diabetes Care for People with Serious Mental Illness - HA1c Testing Poor Control (>9%) (HPCMI): B. Age 65-75 Years
- Diabetes Short-Term Complications Admission Rate (PQI01)
- Diabetes Short-Term Complications Admission Rate (PQI01): A. Age 18-64 Years
- Diabetes Short-Term Complications Admission Rate (PQI01): B. Age 65 and Older
- Glycemic Status Assessment for Patients with Diabetes (Glycemic status <8.0%) (GSD): A. Age 18 to 64
- Glycemic Status Assessment for Patients with Diabetes (Glycemic status <8.0%) (GSD): B. Age 65 to 75
- Glycemic Status Assessment for Patients with Diabetes (Glycemic status >9.0%) (GSD): A. Age 18 to 64
- Glycemic Status Assessment for Patients with Diabetes (Glycemic status >9.0%) (GSD): B. Age 65 to 75
- Heart Failure Admission Rate (PQI08)
- Heart Failure Admission Rate (PQI08): A. Age 18-64 Years
- Heart Failure Admission Rate (PQI08): B. Age 65 and Older
- Medical Assistance with Smoking and Tobacco Use Cessation: Advising Smokers and Tobacco Users to Quit (MSC, CMS Adult Core Set)
- Medical Assistance with Smoking and Tobacco Use Cessation: Discussing Cessation Medications (MSC, CMS Adult Core Set)
- Medical Assistance with Smoking and Tobacco Use Cessation: Discussing Cessation Strategies (MSC, CMS Adult Core Set)
- Postpartum Depression Screening and Follow-Up (PDS) - Depression Screening: A. Age under 21 Years
- Postpartum Depression Screening and Follow-Up (PDS) - Depression Screening: B. Age 21 and over
- Postpartum Depression Screening and Follow-Up (PDS) - Follow-Up on Positive Screen: A. Age Under 21 Years
- Postpartum Depression Screening and Follow-Up (PDS) - Follow-Up on Positive Screen: B. Age 21 and Over.
- Prenatal Immunization Status (PRS): Combination: A. Age Under 21 Years.
- Prenatal Immunization Status (PRS): Combination: B: Age 21 and Over
- Prenatal Immunization Status (PRS): Influenza: A. Age Under 21 Years
- Prenatal Immunization Status (PRS): Influenza: B: Age 21 and Over
- Prenatal Immunization Status (PRS): Tdap: A. Age Under 21 Years
- Prenatal Immunization Status (PRS): Tdap: B: Age 21 and Over
- Screening for Depression and Follow-Up Plan (CDF)
- Screening for Depression and Follow-Up Plan (CDF): A. Age 12 to 17 Years
- Screening for Depression and Follow-Up Plan (CDF): B. Age 18 to 64 Years
- Screening for Depression and Follow-Up Plan (CDF): C. Age 65 and Older
- Use of Opioids at High Dosage in Persons Without Cancer (OHD): A. Age 18 to 64 Years
- Use of Opioids at High Dosage in Persons Without Cancer (OHD): B. Age 65 and Older
- Use of Pharmacotherapy for Opioid Use Disorder - Buprenorphine (OUD)
- Use of Pharmacotherapy for Opioid Use Disorder - Long-Acting, Injectable Naltrexone (OUD)
- Use of Pharmacotherapy for Opioid Use Disorder - Methadone (OUD)
- Use of Pharmacotherapy for Opioid Use Disorder - Oral Naltrexone (OUD)
- Use of Pharmacotherapy for Opioid Use Disorder - Total (OUD)
Back to top
Hospital Inpatient and Outpatient Care - Adults
Back to top
Long Term Community Based Care - Adults
Back to top